博濟醫藥(300404.SZ)擬推250萬份股票期權激勵計劃
格隆匯 9 月 29日丨博濟醫藥(300404.SZ)披露2020年股票期權激勵計劃(草案),此次激勵計劃擬授予股票期權數量為250萬份,約佔該激勵計劃草案公告時公司股本總額2.27億股的1.10%。每份股票期權擁有在滿足行權條件的情況下,在有效期內以行權價格購買1股公司股票的權利。任何一名激勵對象通過全部有效的股權激勵計劃獲授的公司股票累計不超過公司股本總額的1%。
該激勵計劃授予的股票期權行權價格為13.41元/股。該激勵計劃授予的激勵對象總人數為74人,包括公司或公司控股子公司任職的中層管理人員、骨幹員工,以及公司董事會認為應當激勵的其他員工。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.